Impact of the Order of Initiation of Fluconazole and Amphotericin B in Sequential or Combination Therapy on Killing of Candida albicans In Vitro and in a Rabbit Model of Endocarditis and Pyelonephritis

ABSTRACT In vitro time-kill studies and a rabbit model of endocarditis and pyelonephritis were used to define the impact that the order of exposure of Candida albicans to fluconazole (FLC) and amphotericin B (AMB), as sequential and combination therapies, had on the susceptibility of C. albicans to AMB and on the outcome. The contribution of FLC-induced resistance to AMB for C. albicans also was assessed. In vitro, AMB monotherapy rapidly killed each of four C. albicans strains; FLC alone was fungistatic. Preincubation of these fungi with FLC for 18 h prior to exposure to AMB decreased their susceptibilities to AMB for 8 to >40 h. Induced resistance to AMB was transient, but the duration of resistance increased with the length of FLC preincubation. Yeast sequentially incubated with FLC followed by AMB plus FLC (FLC→AMB+FLC) showed fungistatic growth kinetics similar to that of fungi that were exposed to FLC alone. This antagonistic effect persisted for at least 24 h. Simultaneous exposure of C. albicans to AMB and FLC [AMB+FLC(simult)] demonstrated activity similar to that with AMB alone for AMB concentrations of ≥1 μg/ml; antagonism was seen using an AMB concentration of 0.5 μg/ml. The in vitro findings accurately predicted outcomes in our rabbit infection model. In vivo, AMB monotherapy and treatment with AMB for 24 h followed by AMB plus FLC (AMB→AMB+FLC) rapidly sterilized kidneys and cardiac vegetations. AMB+FLC(simult) and FLC→AMB treatments were slower in clearing fungi from infected tissues. FLC monotherapy and FLC→AMB+FLC were both fungistatic and were the least active regimens. No adverse interaction was observed between AMB and FLC for the AMB→FLC regimen. However, FLC→AMB treatment was slower than AMB alone in clearing fungi from tissues. Thus, our in vitro and in vivo studies both demonstrate that preexposure of C. albicans to FLC reduces fungal susceptibility to AMB. The length of FLC preexposure and whether AMB is subsequently used alone or in combination with FLC determine the duration of induced resistance to AMB.

[1]  Michael H. Miller,et al.  Efficacies of High-Dose Fluconazole plus Amphotericin B and High-Dose Fluconazole plus 5-Fluorocytosine versus Amphotericin B, Fluconazole, and 5-Fluorocytosine Monotherapies in Treatment of Experimental Endocarditis, Endophthalmitis, and Pyelonephritis Due to Candida albicans , 1999, Antimicrobial Agents and Chemotherapy.

[2]  Michael H. Miller,et al.  Interaction between Fluconazole and Amphotericin B in Mice with Systemic Infection Due to Fluconazole-Susceptible or -Resistant Strains of Candida albicans , 1999, Antimicrobial Agents and Chemotherapy.

[3]  M. Halpern,et al.  The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  Michael H. Miller,et al.  Pharmacokinetic Studies of Fluconazole in Rabbits Characterizing Doses Which Achieve Peak Levels in Serum and Area under the Concentration-Time Curve Values Which Mimic Those of High-Dose Fluconazole in Humans , 1998, Antimicrobial Agents and Chemotherapy.

[5]  Russell E. Lewis,et al.  Assessment of Antifungal Activities of Fluconazole and Amphotericin B Administered Alone and in Combination againstCandida albicans by Using a Dynamic In Vitro Mycotic Infection Model , 1998, Antimicrobial Agents and Chemotherapy.

[6]  A. Sugar,et al.  Interactions of itraconazole with amphotericin B in the treatment of murine invasive candidiasis. , 1998, The Journal of infectious diseases.

[7]  Michael H. Miller,et al.  Pharmacodynamics of Fluconazole in a Murine Model of Systemic Candidiasis , 1998, Antimicrobial Agents and Chemotherapy.

[8]  M. Ghannoum,et al.  Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models , 1997, Antimicrobial agents and chemotherapy.

[9]  W. Wilmanns,et al.  Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients , 1997, Antimicrobial agents and chemotherapy.

[10]  J. Vazquez,et al.  In vitro interaction between amphotericin B and azoles in Candida albicans , 1996, Antimicrobial agents and chemotherapy.

[11]  E. Anaissie,et al.  Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  J. Montoro,et al.  Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia , 1996, Antimicrobial agents and chemotherapy.

[13]  R. Farinotti,et al.  Comparison of fluconazole and amphotericin B for treatment of experimental Candida albicans endocarditis in rabbits , 1996, Antimicrobial agents and chemotherapy.

[14]  P. Troke,et al.  Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B , 1995, Antimicrobial agents and chemotherapy.

[15]  M. Levenstein,et al.  A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia , 1994 .

[16]  M. Burroughs,et al.  Pharmacokinetics of fluconazole in cerebrospinal fluid and serum of rabbits: validation of an animal model used to measure drug concentrations in cerebrospinal fluid , 1994, Antimicrobial Agents and Chemotherapy.

[17]  S Bhakdi,et al.  Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum , 1994, Antimicrobial Agents and Chemotherapy.

[18]  T. Walsh,et al.  Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits , 1994, Antimicrobial Agents and Chemotherapy.

[19]  C. Beck-Sague,et al.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. , 1993, The Journal of infectious diseases.

[20]  N. Charlier,et al.  Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. , 1992, BMJ.

[21]  M. Witt,et al.  Comparison of fluconazole and amphotericin B for prevention and treatment of experimental Candida endocarditis , 1991, Antimicrobial Agents and Chemotherapy.

[22]  T. Rogers,et al.  Interactions in vitro between polyenes and imidazoles against yeasts. , 1991, The Journal of antimicrobial chemotherapy.

[23]  R F Woolson,et al.  Hospital-acquired candidemia. The attributable mortality and excess length of stay. , 1988, Archives of internal medicine.

[24]  T. Walsh,et al.  Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits. , 1988, Laboratory animal science.

[25]  D. Krogstad,et al.  Sensitive high-pressure liquid chromatographic assay for amphotericin B which incorporates an internal standard , 1986, Antimicrobial Agents and Chemotherapy.

[26]  J. Solomkin,et al.  Indications for therapy for fungemia in postoperative patients. , 1982, Archives of surgery.

[27]  J. Graybill,et al.  Sensitive bioassay for ketoconazole in serum and cerebrospinal fluid , 1981, Antimicrobial Agents and Chemotherapy.

[28]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[29]  R. Bannatyne,et al.  Discrepant Results of Amphotericin B Assays on Fresh Versus Frozen Serum Samples , 1977, Antimicrobial Agents and Chemotherapy.

[30]  H. Akaike.  A new look at the statistical model identification , 1974 .

[31]  D. Durack,et al.  Experimental bacterial endocarditis. 3. Production and progress of the disease in rabbits. , 1973, British journal of experimental pathology.